Fink G D, Montgomery J A, David F, Garneau M, Livni E, Elmaleh D, Strauss H W, Brunengraber H
Department of Biochemistry, University of Montreal, Canada.
J Nucl Med. 1990 Nov;31(11):1823-30.
The metabolism of beta-methyl-[1-14C]heptadecanoic acid, a potential myocardial imaging agent, was investigated in perfused hearts and livers from rats. Hepatic uptake is approximately 4.5 times greater than cardiac uptake. In the heart, 66% of beta-methyl-heptadecanoic acid metabolism occurs via omega-oxidation, 33% by esterification and less than 1% via alpha-oxidation. In contrast, 53% of hepatic metabolism of beta-methyl-heptadecanoic acid occurs via alpha-oxidation, 27% via omega-oxidation, and 20% via esterification. Perfusion of hearts and livers with concentrations of beta-methyl-heptadecanoic acid 100 to 1000 times greater than that used for myocardial imaging does not alter any of the physiological and biochemical parameters measured. In the perfused liver, 3-methyl-[1-14C]glutarate was identified as the principal hydrosoluble catabolite of beta-methyl-heptadecanoic acid.
对一种潜在的心肌显像剂β-甲基-[1-¹⁴C]十七烷酸在大鼠灌流心脏和肝脏中的代谢情况进行了研究。肝脏摄取量约比心脏摄取量大4.5倍。在心脏中,β-甲基十七烷酸代谢的66%通过ω-氧化发生,33%通过酯化,通过α-氧化的不到1%。相比之下,β-甲基十七烷酸的肝脏代谢53%通过α-氧化发生,27%通过ω-氧化,20%通过酯化。用比心肌显像所用浓度高100至1000倍的β-甲基十七烷酸灌注心脏和肝脏,不会改变所测的任何生理和生化参数。在灌流肝脏中,3-甲基-[1-¹⁴C]戊二酸被鉴定为β-甲基十七烷酸的主要水溶性分解代谢产物。